First Horizon Advisors, Inc. C4 Therapeutics, Inc. Transaction History

First Horizon Advisors, Inc.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$3.1 - $9.02 $291 - $847	-94 Reduced 9.23%	924 $2,000
Q4 2022 Feb 10, 2023	BUY	$5.42 - $10.24 $16 - $30	3 Added 0.3%	1,018 $6,000
Q3 2022 Nov 09, 2022	BUY	$8.03 - $12.77 $1,092 - $1,736	136 Added 15.47%	1,015 $8,000
Q2 2022 Aug 02, 2022	BUY	$5.06 - $26.46 $4,371 - $22,861	864 Added 5760.0%	879 $6,000
Q1 2022 May 10, 2022	BUY	$19.99 - $33.23 $299 - $498	15 New	15 $0

130

63.5M

670K

54.8K

Ticker CCCC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,913,800
Market Cap $214M
Description
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting ...

Get notified when there are updates to the investment portfolio of First Horizon Advisors, Inc., based on Form 13F filings with the SEC.

Stay updated on First Horizon Advisors, Inc. with notifications on news.